1 results match your criteria: "Hospital General Regional UMF No. 1[Affiliation]"
Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin.
Ann Hepatol
November 2011
Departamento de Gastroenterología y Hepatología, Hospital General Regional UMF No. 1, Instituto Mexicano del Seguro Social. Cuernavaca, Morelos, México.
Background: Thrombocytopenia is a common hematologic disorder observed in patients with chronic hepatitis C virus (HCV) infection. Combined peginterferon (PEG-INF) and ribavirin treatment may exacerbate thrombocytopenia in patients with HCV.
Objective: The aim of this pilot clinical trial was to assess the efficacy, tolerability and safety of Danazol in thrombocytopenia associated with PEG-INF and ribavirin treatment in patients with HCV.